Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04416035 | A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC(NSCLC) | unknown | Phase 3 | 608 | Zhejiang Teruisi Pharmaceutical Inc.INDUSTRY | 1 | Aug 31, 2020 | clinicaltrials |
| NCT04500704 | Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC(ACROSS1) | unknown | Phase 3 | 166 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
| 1 |
| Aug 5, 2020 |
| clinicaltrials |
| NCT04500717 | Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation(ACROSS2) | unknown | Phase 3 | 460 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT04203485 | Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC) | unknown | Phase 3 | 762 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | May 8, 2020 | clinicaltrials |
| NCT02076477 | The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC）(OITROLC) | unknown | Phase 3 | 420 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT01405079 | Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation(ADJUVANT) | unknown | Phase 3 | 222 | Guangdong Association of Clinical TrialsOTHER | 1 | Feb 18, 2020 | clinicaltrials |
| NCT04254471 | This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients | unknown | Phase 2 / Phase 3 | 313 | Haihe Biopharma Co., Ltd.INDUSTRY | 1 | Feb 5, 2020 | clinicaltrials |
| NCT02416739 | Anticancer Activity of Nicotinamide on Lung Cancer | unknown | Phase 2 / Phase 3 | 110 | Il Yeong Park, Ph.D.OTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT04239833 | A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | unknown | Phase 3 | 240 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 0 | Jan 27, 2020 | clinicaltrials |
| NCT03827577 | OMEGA, Local Ablative Therapy in Oligometastatic NSCLC(OMEGA) | unknown | Phase 3 | 195 | Azienda Ospedaliera Universitaria Integrata VeronaOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT04192682 | Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer | unknown | Phase 2 / Phase 3 | 40 | Changzhou Cancer Hospital of Soochow UniversityOTHER | 1 | Jan 6, 2020 | clinicaltrials |
| NCT04009317 | Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 3 | 260 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
| NCT04073550 | Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer | unknown | Phase 3 | 184 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 29, 2019 | clinicaltrials |
| NCT02759783 | Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases(CORE) | unknown | Phase 2 / Phase 3 | 245 | Royal Marsden NHS Foundation TrustOTHER | 2 | Aug 21, 2019 | clinicaltrials |
| NCT04058704 | A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy(SMART) | unknown | Phase 3 | 296 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 15, 2019 | clinicaltrials |
| NCT03992885 | Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations. | unknown | Phase 3 | 70 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 20, 2019 | clinicaltrials |
| NCT03244605 | Efficacy Study of Comprehensive Rehabilitation Program in Postoperative NSCLC Patients | unknown | Phase 3 | 236 | Shanghai University of Traditional Chinese MedicineOTHER | 1 | Jun 12, 2019 | clinicaltrials |
| NCT03372694 | Efficacy Study of Comprehensive Rehabilitation Program Plus Chemotherapy in Postoperative NSCLC Patients | unknown | Phase 3 | 354 | Shanghai University of Traditional Chinese MedicineOTHER | 1 | Jun 12, 2019 | clinicaltrials |
| NCT03428022 | Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC(AFLC) | unknown | Phase 3 | 54 | Shenzhen People's HospitalOTHER | 1 | Apr 4, 2019 | clinicaltrials |
| NCT03884192 | Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC(CONSIST) | unknown | Phase 3 | 162 | Shandong Cancer Hospital and InstituteOTHER | 1 | Mar 21, 2019 | clinicaltrials |
| NCT03856697 | Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation | unknown | Phase 3 | 406 | Hangzhou ACEA Pharmaceutical Research Co., Ltd.INDUSTRY | 1 | Feb 27, 2019 | clinicaltrials |
| NCT03700333 | Clinical Research of S-1 Versus Pemetrexed in the Maintenance Treatment of Advanced NSNSCLC | unknown | Phase 3 | 120 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Oct 9, 2018 | clinicaltrials |
| NCT01407822 | Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer(EMERGING) | unknown | Phase 2 / Phase 3 | 72 | Guangdong Association of Clinical TrialsOTHER | 1 | Sep 11, 2018 | clinicaltrials |
| NCT03656393 | To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma(RCTACSCNSCLC) | unknown | Phase 3 | 48 | Shenzhen People's HospitalOTHER | 1 | Sep 4, 2018 | clinicaltrials |
| NCT03651219 | Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer | unknown | Phase 3 | 90 | Beijing Chest HospitalOTHER | 0 | Aug 29, 2018 | clinicaltrials |
| NCT03533127 | A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer | unknown | Phase 3 | 648 | Luye Pharma Group Ltd.INDUSTRY | 1 | Jul 10, 2018 | clinicaltrials |
| NCT03432637 | Clinical Trial of Thoracoscopic Lobecotmy Under Spontaneous Ventilating Anesthesia | unknown | Phase 3 | 450 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Feb 26, 2018 | clinicaltrials |
| NCT03262948 | Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin in Advanced Squamous Cell Non Small Cell Lung Cancer | unknown | Phase 3 | 388 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Nov 13, 2017 | clinicaltrials |
| NCT03331575 | Hypofractionated vs. Conventionally Fractionated Concurrent CRT for Unresectable Stage III NSCLC(HCFCCUSN) | unknown | Phase 3 | 480 | Shanghai Chest HospitalOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT02714010 | EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC | unknown | Phase 3 | 601 | Sun Yat-sen UniversityOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT02455843 | Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC | unknown | Phase 3 | 275 | Shandong Provincial HospitalOTHER_GOV | 1 | Sep 19, 2017 | clinicaltrials |
| NCT03269162 | Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection | unknown | Phase 3 | 144 | lihegenOTHER | 0 | Sep 14, 2017 | clinicaltrials |
| NCT01014130 | Hypofractionated Radiotherapy (Stereotactic) Versus Conventional Radiotherapy for Inoperable Early Stage I Non-small Cell Lung Cancer (NSCLC)(CHISEL) | unknown | Phase 3 | 101 | Trans Tasman Radiation Oncology GroupOTHER | 2 | Jul 12, 2017 | clinicaltrials |
| NCT02896166 | Microwave Ablation in the Treatment of Stage I Non Small Cell Lung Cancer | unknown | Phase 3 | 150 | Shandong Provincial HospitalOTHER_GOV | 1 | Jun 14, 2017 | clinicaltrials |
| NCT03074864 | Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC(TREND) | unknown | Phase 2 / Phase 3 | 90 | Guangdong Provincial People's HospitalOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT02332512 | Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)(ANSWER) | unknown | Phase 3 | 417 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 24, 2017 | clinicaltrials |
| NCT02029209 | To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer | unknown | Phase 2 / Phase 3 | 110 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 16, 2016 | clinicaltrials |
| NCT02972333 | Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M | unknown | Phase 3 | 150 | Shandong Cancer Hospital and InstituteOTHER | 0 | Nov 23, 2016 | clinicaltrials |
| NCT02579564 | Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients | unknown | Phase 3 | 134 | Xinqiao Hospital of ChongqingOTHER | 0 | Oct 21, 2016 | clinicaltrials |
| NCT02938546 | 18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study | unknown | Phase 3 | 200 | Shanghai Chest HospitalOTHER | 0 | Oct 21, 2016 | clinicaltrials |
| NCT02360761 | Surgical Treatment of Elderly Patients With cT1N0M0 Non-small Cell Lung Cancer Comparison Between Sublobar Resection and Lobectomy(STEPS) | unknown | Phase 3 | 339 | Peking University People's HospitalOTHER | 1 | Sep 20, 2016 | clinicaltrials |
| NCT02802540 | Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients | unknown | Phase 2 / Phase 3 | 78 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT02883543 | First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation | unknown | Phase 3 | 330 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | Aug 30, 2016 | clinicaltrials |
| NCT02879097 | Efficacy-Safety-Immunogenicity Study of CBT124&EU-sourced Avastin® in Stage 4 NSCLC | unknown | Phase 3 | 200 | Cipla BioTec Pvt. Ltd.INDUSTRY | 0 | Aug 25, 2016 | clinicaltrials |
| NCT02875457 | Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin | unknown | Phase 3 | 100 | Third Military Medical UniversityOTHER | 0 | Aug 24, 2016 | clinicaltrials |
| NCT02859077 | EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism | unknown | Phase 3 | 100 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Aug 9, 2016 | clinicaltrials |
| NCT01460472 | Immunotherapy With Racotumomab in Advanced Lung Cancer | unknown | Phase 3 | 1,082 | Recombio SLINDUSTRY | 7 | Jul 29, 2016 | clinicaltrials |
| NCT01882621 | Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Cisplatin Contained Chemotherapy in NSCLC Patients | unknown | Phase 3 | 300 | Sun Yat-sen UniversityOTHER | 1 | Jun 1, 2016 | clinicaltrials |
| NCT02780778 | Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer | unknown | Phase 2 / Phase 3 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 23, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Aug 31, 2020source: clinicaltrials